Search research articles
Contact Us
Filters
Showing results (131-140 of 164) with videos related to
Page
of 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 27, 2023
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up
Andrew J Davies, Sharon Barrans, Louise Stanton, et al.
JAMA Network Open
|
February 21, 2022
Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19
Csilla Várnai, Claire Palles, Roland Arnold, et al.
Blood Advances
|
September 11, 2020
Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma
Stephen Booth, Hannah Plaschkes, Amy A Kirkwood, et al.
Blood Advances
|
August 31, 2021
A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial
Christopher P Fox, Ayesha S Ali, Graham McIlroy, et al.
The Lancet. Oncology
|
April 6, 2019
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
Andrew Davies, Thomas E Cummin, Sharon Barrans, et al.
The Lancet. Haematology
|
April 29, 2018
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial
Mary Gleeson, Clare Peckitt, Ye Mong To, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 8, 2025
CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial
Lara E Buermann, Louise Stanton, Matthew J J Rose-Zerilli, et al.
British Journal of Haematology
|
March 8, 2026
Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival
Maeve A O'Reilly, William Wilson, Bernard Maybury, et al.
Leukemia & Lymphoma
|
July 16, 2021
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies
Graham P Collins, Tracy N Clevenger, Kathleen A Burke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 3, 2018
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
Margaretha G M Roemer, Robert A Redd, Fathima Zumla Cader, et al.
Page
of 17
Search research articles
Search
Showing results (131-140 of 164) with videos related to
Sort By:
Page
of 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 27, 2023
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up
Andrew J Davies, Sharon Barrans, Louise Stanton, et al.
JAMA Network Open
|
February 21, 2022
Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19
Csilla Várnai, Claire Palles, Roland Arnold, et al.
Blood Advances
|
September 11, 2020
Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma
Stephen Booth, Hannah Plaschkes, Amy A Kirkwood, et al.
Blood Advances
|
August 31, 2021
A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial
Christopher P Fox, Ayesha S Ali, Graham McIlroy, et al.
The Lancet. Oncology
|
April 6, 2019
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
Andrew Davies, Thomas E Cummin, Sharon Barrans, et al.
The Lancet. Haematology
|
April 29, 2018
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial
Mary Gleeson, Clare Peckitt, Ye Mong To, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 8, 2025
CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial
Lara E Buermann, Louise Stanton, Matthew J J Rose-Zerilli, et al.
British Journal of Haematology
|
March 8, 2026
Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival
Maeve A O'Reilly, William Wilson, Bernard Maybury, et al.
Leukemia & Lymphoma
|
July 16, 2021
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies
Graham P Collins, Tracy N Clevenger, Kathleen A Burke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 3, 2018
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
Margaretha G M Roemer, Robert A Redd, Fathima Zumla Cader, et al.
Page
of 17